We focus on some of the most promising medical radioisotopes for targeted radiotherapy. Our innovative equipment and efficient supply chains will allow to improve the accessibility and supply security of GMP-grade radioisotopes worldwide.
nca Lutetium-177 is the most widely used radionuclide for targeted cancer radiotherapy. It is the active substance of 177Lu-PSMA-617 and more than 150 clinical-stage therapeutic drug developments across multiple cancer indications.
nca Lu-177 is a beta emitter with a half-life of 6.7 days that is free of the long-lived 177mLu. Linked to a cancer-specific targeting agent, it can destroy cancer cells over a distance of one millimeter.
Actinium-225 is currently the most sought-after radioisotope for alphatherapy. It is present in the therapeutic pipeline of many up-and-coming radiopharmaceutical companies.
225Ac is an alpha emitter with a half-life of 9.9 days, which delivers its cell-killing energy over a very short distance of about the thickness of six cells. The similar radiolabeling characterics of Actinium and Lutetium makes 225Ac the natural apha counterpart to 177Lu.
Terbium-161 has garnered great interest in nuclear medicine due to its complementarity with other radiosotopes of the Terbium family: Tb-149 (alpha-emitter), Tb-152 (PET), Tb-155 (SPECT).
161Tb is a beta emitter with a half-life of 6.9 days that shows similar characteristics to nca 177Lu, but may have enhanced short distance cell-killing efficiency due to the co-emission of a larger number of conversion and Auger electrons.